These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 8374556)

  • 1. Liver iron overload and liver fibrosis in thalassemia.
    Angelucci E; Baronciani D; Lucarelli G; Giardini C; Galimberti M; Polchi P; Martinelli F; Baldassarri M; Muretto P
    Bone Marrow Transplant; 1993; 12 Suppl 1():29-31. PubMed ID: 8374556
    [No Abstract]   [Full Text] [Related]  

  • 2. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract]   [Full Text] [Related]  

  • 3. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver.
    Mazza P; Giua R; De Marco S; Bonetti MG; Amurri B; Masi C; Lazzari G; Rizzo C; Cervellera M; Peluso A
    Haematologica; 1995; 80(5):398-404. PubMed ID: 8566878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia.
    Chen AC; Peng CT; Wu SF; Wu KH; Chiang IP; Tsai CH
    Hemoglobin; 2006; 30(2):209-14. PubMed ID: 16798645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 6. The treatment of Cooley's anemia.
    Nathan DG
    Haematologica; 1990; 75 Suppl 5():57-65. PubMed ID: 2086382
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatitis C virus infection and liver disease in children with thalassemia.
    Locasciulli A; Monguzzi W; Tornotti G; Bianco P; Masera G
    Bone Marrow Transplant; 1993; 12 Suppl 1():18-20. PubMed ID: 7690633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia.
    Risdon RA; Barry M; Flynn DM
    J Pathol; 1975 Jun; 116(2):83-95. PubMed ID: 1151528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods for noninvasive measurement of tissue iron in Cooley's anemia.
    Sheth S; Tang H; Jensen JH; Altmann K; Prakash A; Printz BF; Hordof AJ; Tosti CL; Azabagic A; Swaminathan S; Brown TR; Olivieri NF; Brittenham GM
    Ann N Y Acad Sci; 2005; 1054():358-72. PubMed ID: 16339684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of iron overload.
    Cohen A; Witzleben C; Schwartz E
    Semin Liver Dis; 1984 Aug; 4(3):228-38. PubMed ID: 6091277
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of hepatitis C virus infection in thalassemia.
    Butensky E; Pakbaz Z; Foote D; Walters MC; Vichinsky EP; Harmatz P
    Ann N Y Acad Sci; 2005; 1054():290-9. PubMed ID: 16339677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron metabolism in thalassemia intermedia.
    Fiorelli G; Fargion S; Piperno A; Battafarano N; Cappellini MD
    Haematologica; 1990; 75 Suppl 5():89-95. PubMed ID: 2086386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B
    Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
    [No Abstract]   [Full Text] [Related]  

  • 16. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
    Marciani MG; Cianciulli P; Stefani N; Stefanini F; Peroni L; Sabbadini M; Maschio M; Trua G; Papa G
    Haematologica; 1991; 76(2):131-4. PubMed ID: 1937171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of iron overload in thalassemia.
    Piomelli S; Graziano J
    Birth Defects Orig Artic Ser; 1982; 18(7):339-46. PubMed ID: 7159742
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of thalassemias: growth and development, hormone substitution, vitamin supplementation, and vaccination.
    Kattamis CA; Kattamis AC
    Semin Hematol; 1995 Oct; 32(4):269-79. PubMed ID: 8560284
    [No Abstract]   [Full Text] [Related]  

  • 19. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.
    Di Marco V; Capra M; Gagliardotto F; Borsellino Z; Cabibi D; Barbaria F; Ferraro D; Cuccia L; Ruffo GB; Bronte F; Di Stefano R; Almasio PL; Craxì A
    Haematologica; 2008 Aug; 93(8):1243-6. PubMed ID: 18556410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical studies on iron chelation in patients with thalassemia major.
    Freedman MH; Olivieri N; Benson L; Liu P; McClelland R; St Louis P; Templeton D; Koren G
    Haematologica; 1990; 75 Suppl 5():74-83. PubMed ID: 2086384
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.